Endocannabinoid system clinical reports

Accumulating electrophysiological and neuroanatomical analyses indicate that some of the CB, CNR receptor is targeted to the presynaptic terminals of neurons where it acts to inhibit release of classical neurotransmitters as reviewed by Elphick and Egertova, (2001). It is therefore tempting to speculate that the endocannabinoid system may be a major player in the reward pathway, particularly as it is one of the most abundant neurochemical systems in the CNS. Other studies report that THC, the major psychoactive constituent in marijuana, inhibits the synaptosomal uptake of dopamine, serotonin, norepinephrine, acetylcholine, and GABA. This, therefore, warrants pre-clinical evaluations to determine the role(s) of the endocannabinoid system in dmg and alcohol dependence and other neuropsychiatric conditions. 

---